Summary: The NovaCross CTO Microcatheter by Nitiloop is designed for crossing chronic total occlusions in coronary arteries. It is FDA 510(k) cleared and supported by multiple studies demonstrating its efficacy and safety in facilitating coronary interventions.
The NovaCross CTO Microcatheter received FDA 510(k) clearance on April 2, 2020. Manufactured by Nitiloop, it is classified as a Class 2 medical device under product code DQY.
What It Is
The NovaCross CTO Microcatheter is a specialized device used in interventional cardiology to facilitate the crossing of chronic total occlusions (CTOs) in coronary arteries. It is designed to enhance guidewire support and improve procedural success in complex coronary interventions.
Clinical Applications
Commonly used in patients with ischemic heart disease due to coronary CTOs, the NovaCross CTO Microcatheter aids in navigating challenging lesions where traditional guidewires may fail. It is particularly useful in percutaneous coronary interventions (PCI) involving complex anatomy.
Evidence Summary
The available literature includes seven studies, comprising randomized controlled trials and prospective studies, evaluating the NovaCross CTO Microcatheter. These studies span from 2017 to 2021, providing a comprehensive overview of its clinical performance.
Reported Outcomes
Published studies report that the NovaCross CTO Microcatheter effectively facilitates the crossing of coronary CTOs, improving procedural success rates. The device has shown promising results in enhancing guidewire support and reducing procedure time in complex coronary interventions.
Safety Profile
Reported complications include minor procedural complications typical of coronary interventions, with no significant adverse events directly attributed to the device. Overall, the safety profile of the NovaCross CTO Microcatheter is consistent with other devices in its class.
Evidence Limitations
Current evidence is limited by the small sample sizes and the lack of long-term follow-up data. Further research is needed to establish the long-term safety and efficacy of the NovaCross CTO Microcatheter in diverse patient populations.
Frequently Asked Questions
What are the clinical indications for NovaCross CTO Microcatheter?
The NovaCross CTO Microcatheter is indicated for use in patients with coronary chronic total occlusions to facilitate guidewire crossing and improve procedural success in percutaneous coronary interventions.
What outcomes have been reported in clinical studies?
Clinical studies have reported improved success rates in crossing coronary CTOs, enhanced guidewire support, and reduced procedure times when using the NovaCross CTO Microcatheter.
What complications have been reported?
Safety data from evidence indicate minor procedural complications typical of coronary interventions, with no significant adverse events directly linked to the NovaCross CTO Microcatheter.
Disclaimer: This page compiles publicly available regulatory and published clinical evidence for educational reference.
It does not constitute medical advice, product endorsement, or a recommendation for clinical use.
Always consult manufacturer documentation and clinical judgment for patient care decisions.
📬 Stay Updated
Get the latest vascular education content delivered to your inbox.